Robert Spiera, MD
Basic profileDirector of the Scleroderma, Vasculitis, and Myositis Center at Hospital for Special Surgery; Professor of Medicine at Weill Cornell Medical College · Hospital for Special Surgery
Robert Spiera is Director of the Scleroderma, Vasculitis, and Myositis Center at Hospital for Special Surgery; Professor of Medicine at Weill Cornell Medical College at Hospital for Special Surgery. OpenAlex indexes 301 publications with 17,096 citations (h-index 63); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Rheumatology profiles in the findmyKOL directory.
Overview
Updated 18 Oct 2026
Robert Spiera, MD, is Director of the Scleroderma, Vasculitis, and Myositis Center at Hospital for Special Surgery. The public record shows 295 publications with 17,265 citations (h-index 63), centered on Vasculitis and related conditions, Systemic Sclerosis and Related Diseases, Systemic Lupus Erythematosus Research. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 15 companies.
- Most recent indexed publication: 2026 · The New England journal of medicine
- Top research focus: Vasculitis and related conditions
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 15 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 147.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1088 Park Avenue
New York, NY 10128-1132
Telephone
212-860-2100Provider last certified this registry record 26 Apr 2021 · collected 28 Jul 2026.
Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:
- TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis
Sponsor: Robert Spiera, MD
- Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Sponsor: Hospital for Special Surgery, New York
Industry payments
Updated 18 Oct 2026
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Galderma Laboratories, L.P.Program year20252 payments
- Boehringer Ingelheim International GmbHProgram year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
41.8%Folate Analog Metabolic Inhibitor16.6%Methotrexate95%Rasuvo5%Part D<11 patientsTNF inhibitor13.8%Enbrel Sureclick46%Humira(Cf) Pen37%Enbrel17%Part D<11 patients+ 5 more classes in this area
Metabolism & gastrointestinal
16%Corticosteroid8.1%Prednisone100%Part D≥27 patientsAntidiarrheal microorganisms5.2%Folic Acid100%Part D<11 patients+ 2 more classes in this area
Antiparasitic
14%Antimalarial14%Hydroxychloroquine Sulfate100%Part D≥54 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica.
The New England journal of medicine
Clinical Trial2026 - Treating skin involvement in diffuse cutaneous systemic sclerosis: results from an international scleroderma specialist survey.
Rheumatology advances in practice
Article2026 - Management of interstitial lung disease in systemic autoimmune rheumatic diseases: a survey of rheumatologists and pulmonologists.
Rheumatology advances in practice
Article2026 - Skin Biopsies Enhance Prediction of Clinical Trajectory in Diffuse Cutaneous Systemic Sclerosis.
Arthritis & rheumatology (Hoboken, N.J.)
Article2026 - A Randomized, Double-Blind, Placebo-Controlled Trial of Abatacept for the Treatment of Relapsing, Nonsevere Granulomatosis With Polyangiitis.
Arthritis & rheumatology (Hoboken, N.J.)
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01Rituximab versus Cyclophosphamide for ANCA-Associated VasculitisArticle2,766 citations2010
- 02Trial of Tocilizumab in Giant-Cell ArteritisArticle1,391 citations2017
- 03Efficacy of Remission-Induction Regimens for ANCA-Associated VasculitisArticle728 citations2013
- 04
- 05
Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/robert-spiera-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
rheumnow.com/therapeutic-update/gpa-patient-and-physician-perspectives-ent-manifestations
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →rheumnow.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on recordEditorial & leadership roles
journal and society appointmentsAwards & honors
honors on the public recordSecondary affiliations
appointments beyond the home institution- NewYork-Presbyterian Hospital
Weill Cornell Medical Center (Attending Physician)
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Teena Shetty, MD
Hospital for Special Surgery
Michael Lockshin, MD
Hospital for Special Surgery
Lionel Ivashkiv, MD
Hospital for Special Surgery
Vivian Bykerk, VIVIAN, BYKERK, MD
Hospital for Special Surgery
Marc Hochberg, MD
University of Maryland School of Medicine
Michelle Petri, MD
Johns Hopkins University School of Medicine
Dinesh Khanna, MD
University of Michigan
Matthew Liang, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”